319 related articles for article (PubMed ID: 23995279)
1. Pharmacological prospects in the treatment of Duchenne muscular dystrophy.
Ruegg UT
Curr Opin Neurol; 2013 Oct; 26(5):577-84. PubMed ID: 23995279
[TBL] [Abstract][Full Text] [Related]
2. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
Miura P; Jasmin BJ
Trends Mol Med; 2006 Mar; 12(3):122-9. PubMed ID: 16443393
[TBL] [Abstract][Full Text] [Related]
3. Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.
Péladeau C; Jasmin BJ
Methods Mol Biol; 2023; 2587():495-510. PubMed ID: 36401046
[TBL] [Abstract][Full Text] [Related]
4. Utrophin upregulation in Duchenne muscular dystrophy.
Hirst RC; McCullagh KJ; Davies KE
Acta Myol; 2005 Dec; 24(3):209-16. PubMed ID: 16629055
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice.
Perronnet C; Chagneau C; Le Blanc P; Samson-Desvignes N; Mornet D; Laroche S; De La Porte S; Vaillend C
Hum Mol Genet; 2012 May; 21(10):2263-76. PubMed ID: 22343141
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
7. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
8. Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies.
Reinig AM; Mirzaei S; Berlau DJ
Pharmacotherapy; 2017 Apr; 37(4):492-499. PubMed ID: 28152217
[TBL] [Abstract][Full Text] [Related]
9. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
Helderman-van den Enden AT; Straathof CS; Aartsma-Rus A; den Dunnen JT; Verbist BM; Bakker E; Verschuuren JJ; Ginjaar HB
Neuromuscul Disord; 2010 Apr; 20(4):251-4. PubMed ID: 20153965
[TBL] [Abstract][Full Text] [Related]
10. Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening.
Moorwood C; Khurana TS
Expert Opin Drug Discov; 2013 May; 8(5):569-81. PubMed ID: 23473647
[TBL] [Abstract][Full Text] [Related]
11. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
[TBL] [Abstract][Full Text] [Related]
12. Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.
Szwec S; Kapłucha Z; Chamberlain JS; Konieczny P
BioDrugs; 2024 Jan; 38(1):95-119. PubMed ID: 37917377
[TBL] [Abstract][Full Text] [Related]
13. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for Duchenne and Becker dystrophies.
Voisin V; de la Porte S
Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414
[TBL] [Abstract][Full Text] [Related]
15. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy.
Chen YW; Nagaraju K; Bakay M; McIntyre O; Rawat R; Shi R; Hoffman EP
Neurology; 2005 Sep; 65(6):826-34. PubMed ID: 16093456
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy.
Fairclough RJ; Perkins KJ; Davies KE
Curr Gene Ther; 2012 Jun; 12(3):206-44. PubMed ID: 22571500
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for muscle disease.
Miyagoe-Suzuki Y; Takeda S
Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
[TBL] [Abstract][Full Text] [Related]
18. Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy.
Shieh PB
Neurotherapeutics; 2018 Oct; 15(4):840-848. PubMed ID: 30414046
[TBL] [Abstract][Full Text] [Related]
19. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.
Charleston JS; Schnell FJ; Dworzak J; Donoghue C; Lewis S; Chen L; Young GD; Milici AJ; Voss J; DeAlwis U; Wentworth B; Rodino-Klapac LR; Sahenk Z; Frank D; Mendell JR
Neurology; 2018 Jun; 90(24):e2146-e2154. PubMed ID: 29752304
[TBL] [Abstract][Full Text] [Related]
20. On the path to a Duchenne muscular dystrophy therapy.
Fallon J
R I Med J (2013); 2013 Feb; 96(2):22-5. PubMed ID: 23641422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
